Loading...
XJPX7774
Market cap123mUSD
Jan 17, Last price  
475.00JPY
1D
-0.42%
1Q
-7.41%
Jan 2017
-67.22%
IPO
6.98%
Name

Japan Tissue Engineering Co Ltd

Chart & Performance

D1W1MN
XJPX:7774 chart
P/E
134.73
P/S
7.67
EPS
3.53
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
1.29%
Revenues
2.51b
+23.70%
111,752,000114,724,000211,659,000351,574,000473,606,000563,704,0001,008,044,0001,321,494,0001,430,826,0002,135,148,0002,271,506,0002,357,917,0002,309,851,0002,257,609,0002,103,443,0002,032,448,0002,514,189,000
Net income
143m
P
-1,086,238,000-1,133,985,000-1,099,917,000-1,156,986,000-1,096,366,000-1,077,686,000-827,837,000-690,527,000-681,539,000276,242,000227,890,000-333,248,000-287,099,000-466,622,000-497,889,000-729,317,000143,169,000
CFO
274m
P
-981,718,000-1,021,897,000-1,021,005,000-1,012,151,000-1,059,155,000-989,987,000-961,315,000-756,723,000-346,906,00054,950,000632,006,000-396,110,000-84,584,000-399,586,000-225,248,000-622,600,000274,138,000

Profile

Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.
URL
https://www.jpte.co.jp/
IPO date
Dec 21, 2007
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
2,514,189
23.70%
2,032,448
-3.38%
2,103,443
-6.83%
Cost of revenue
2,286,332
1,562,807
1,525,682
Unusual Expense (Income)
NOPBT
227,857
469,641
577,761
NOPBT Margin
9.06%
23.11%
27.47%
Operating Taxes
3,840
3,840
3,840
Tax Rate
1.69%
0.82%
0.66%
NOPAT
224,017
465,801
573,921
Net income
143,169
-119.63%
(729,317)
46.48%
(497,889)
6.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
(20)
BB yield
0.00%
Debt
Debt current
133
803
Long-term debt
133
1,069
Deferred revenue
Other long-term liabilities
34,900
34,900
34,901
Net debt
(4,266,364)
(4,134,324)
(4,931,467)
Cash flow
Cash from operating activities
274,138
(622,600)
(225,248)
CAPEX
(196,000)
(175,997)
(117,230)
Cash from investing activities
(242,230)
1,124,654
(116,479)
Cash from financing activities
(134)
(803)
(823)
FCF
211,512
463,183
749,025
Balance
Cash
4,266,344
4,134,570
4,933,319
Long term investments
20
20
20
Excess cash
4,140,655
4,032,968
4,828,167
Stockholders' equity
3,291,888
3,148,718
3,878,036
Invested Capital
2,823,355
2,799,928
2,798,292
ROIC
7.97%
16.64%
20.46%
ROCE
3.73%
7.89%
8.65%
EV
Common stock shares outstanding
40,610
40,610
40,610
Price
683.00
31.09%
521.00
1.56%
513.00
-32.05%
Market cap
27,736,599
31.09%
21,157,787
1.56%
20,832,909
-32.05%
EV
23,470,235
17,023,463
15,901,442
EBITDA
361,905
601,094
702,734
EV/EBITDA
64.85
28.32
22.63
Interest
Interest/NOPBT